The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer
Identifieur interne : 003942 ( Istex/Corpus ); précédent : 003941; suivant : 003943The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer
Auteurs : Nizar Habal ; Armando E. Giuliano ; Donald L. MortonSource :
- Seminars in Oncology [ 0093-7754 ] ; 2001.
Abstract
Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.
Url:
DOI: 10.1016/S0093-7754(01)90044-2
Links to Exploration step
ISTEX:7A7AE56241211D63D73EFA367CB8AD1BF783D287Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title><author><name sortKey="Habal, Nizar" sort="Habal, Nizar" uniqKey="Habal N" first="Nizar" last="Habal">Nizar Habal</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Giuliano, Armando E" sort="Giuliano, Armando E" uniqKey="Giuliano A" first="Armando E" last="Giuliano">Armando E. Giuliano</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Morton, Donald L" sort="Morton, Donald L" uniqKey="Morton D" first="Donald L" last="Morton">Donald L. Morton</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7A7AE56241211D63D73EFA367CB8AD1BF783D287</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S0093-7754(01)90044-2</idno><idno type="url">https://api.istex.fr/document/7A7AE56241211D63D73EFA367CB8AD1BF783D287/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003942</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003942</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title><author><name sortKey="Habal, Nizar" sort="Habal, Nizar" uniqKey="Habal N" first="Nizar" last="Habal">Nizar Habal</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Giuliano, Armando E" sort="Giuliano, Armando E" uniqKey="Giuliano A" first="Armando E" last="Giuliano">Armando E. Giuliano</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author><author><name sortKey="Morton, Donald L" sort="Morton, Donald L" uniqKey="Morton D" first="Donald L" last="Morton">Donald L. Morton</name><affiliation><mods:affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Oncology</title><title level="j" type="abbrev">YSONC</title><idno type="ISSN">0093-7754</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="41">41</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0093-7754</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0093-7754</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>node</json:string><json:string>melanoma</json:string><json:string>slnd</json:string><json:string>surg</json:string><json:string>axillary</json:string><json:string>nodal</json:string><json:string>lymphatic</json:string><json:string>metastasis</json:string><json:string>lymphadenectomy</json:string><json:string>intraoperative</json:string><json:string>oncol</json:string><json:string>alnd</json:string><json:string>breast cancer</json:string><json:string>sentinel</json:string><json:string>giuliano</json:string><json:string>cutaneous</json:string><json:string>adjuvant</json:string><json:string>tracer</json:string><json:string>nonsentinel</json:string><json:string>prognostic</json:string><json:string>lymph</json:string><json:string>elnd</json:string><json:string>clin</json:string><json:string>randomized</json:string><json:string>colloid</json:string><json:string>radiocolloid</json:string><json:string>lymphoscintigraphy</json:string><json:string>excision</json:string><json:string>occult</json:string><json:string>carcinoma</json:string><json:string>radiotracer</json:string><json:string>habal</json:string><json:string>malignant</json:string><json:string>krag</json:string><json:string>primary tumor</json:string><json:string>semin</json:string><json:string>lymph nodes</json:string><json:string>dissection</json:string><json:string>nodal disease</json:string><json:string>sentinel lymphadenectomy</json:string><json:string>surg oncol</json:string><json:string>nonsentinel nodes</json:string><json:string>sentinel node</json:string><json:string>positive node</json:string><json:string>positive nodes</json:string><json:string>recurrence</json:string><json:string>negative nodes</json:string><json:string>wide excision</json:string><json:string>overall survival</json:string><json:string>gamma probe</json:string><json:string>intraoperative lymphatic mapping</json:string><json:string>primary breast cancer</json:string><json:string>breast</json:string><json:string>biopsy</json:string><json:string>john wayne cancer institute</json:string><json:string>primary breast carcinoma</json:string><json:string>current status</json:string><json:string>axillary basins</json:string><json:string>complete node dissection</json:string><json:string>adjuvant therapy</json:string><json:string>tumor status</json:string><json:string>axillary nodes</json:string><json:string>nodal status</json:string><json:string>radioactive count</json:string><json:string>nodal dissection</json:string><json:string>identification rates</json:string><json:string>lymph node</json:string><json:string>sentinel lymph node</json:string><json:string>observation group</json:string><json:string>sentinel cancer</json:string><json:string>clin oncol</json:string><json:string>technical details</json:string></teeft></keywords><author><json:item><name>Nizar Habal</name><affiliations><json:string>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</json:string></affiliations></json:item><json:item><name>Armando E Giuliano</name><affiliations><json:string>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</json:string></affiliations></json:item><json:item><name>Donald L Morton</name><affiliations><json:string>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.</abstract><qualityIndicators><score>6.08</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>631</abstractCharCount><pdfWordCount>5565</pdfWordCount><pdfCharCount>48194</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>90</abstractWordCount></qualityIndicators><title>The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title><pii><json:string>S0093-7754(01)90044-2</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Semin Oncol</title><language><json:string>unknown</json:string></language><volume>25</volume><pages><first>611</first><last>622</last></pages></serie><host><title>Seminars in Oncology</title><language><json:string>unknown</json:string></language><publicationDate>2001</publicationDate><issn><json:string>0093-7754</json:string></issn><pii><json:string>S0093-7754(00)X0063-2</json:string></pii><volume>28</volume><issue>1</issue><pages><first>41</first><last>52</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>oncology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1016/S0093-7754(01)90044-2</json:string></doi><id>7A7AE56241211D63D73EFA367CB8AD1BF783D287</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/7A7AE56241211D63D73EFA367CB8AD1BF783D287/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/7A7AE56241211D63D73EFA367CB8AD1BF783D287/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7A7AE56241211D63D73EFA367CB8AD1BF783D287/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>2001</date></publicationStmt><notesStmt><note>Supported by Grant No. CA29605 from the National Cancer Institute and by funding from the Wrather Family Foundation (Los Angeles), the Ben B. and Joyce E. Eisenberg Foundation (Los Angeles), the Associates for Breast Cancer Research, and the Fashion Footwear Association of New York.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title><author xml:id="author-0000"><persName><forename type="first">Nizar</forename><surname>Habal</surname></persName><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Armando E</forename><surname>Giuliano</surname></persName><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Donald L</forename><surname>Morton</surname></persName><note type="biography">Address reprint requests to Donald Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.</note><affiliation>Address reprint requests to Donald Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.</affiliation><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation></author><idno type="istex">7A7AE56241211D63D73EFA367CB8AD1BF783D287</idno><idno type="DOI">10.1016/S0093-7754(01)90044-2</idno><idno type="PII">S0093-7754(01)90044-2</idno></analytic><monogr><title level="j">Seminars in Oncology</title><title level="j" type="abbrev">YSONC</title><idno type="pISSN">0093-7754</idno><idno type="PII">S0093-7754(00)X0063-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="41">41</biblScope><biblScope unit="page" to="52">52</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.</p></abstract></profileDesc><revisionDesc><change when="2001">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/7A7AE56241211D63D73EFA367CB8AD1BF783D287/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>YSONC</jid><aid>01900442</aid><ce:pii>S0093-7754(01)90044-2</ce:pii><ce:doi>10.1016/S0093-7754(01)90044-2</ce:doi><ce:copyright type="unknown" year="2001"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Supported by Grant No. CA29605 from the National Cancer Institute and by funding from the Wrather Family Foundation (Los Angeles), the Ben B. and Joyce E. Eisenberg Foundation (Los Angeles), the Associates for Breast Cancer Research, and the Fashion Footwear Association of New York.</ce:note-para></ce:article-footnote><ce:title>The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</ce:title><ce:author-group><ce:author><ce:given-name>Nizar</ce:given-name><ce:surname>Habal</ce:surname></ce:author><ce:author><ce:given-name>Armando E</ce:given-name><ce:surname>Giuliano</ce:surname></ce:author><ce:author><ce:given-name>Donald L</ce:given-name><ce:surname>Morton</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address reprint requests to Donald Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer</title></titleInfo><name type="personal"><namePart type="given">Nizar</namePart><namePart type="family">Habal</namePart><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Armando E</namePart><namePart type="family">Giuliano</namePart><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Donald L</namePart><namePart type="family">Morton</namePart><affiliation>Roy E. Coats Research Laboratories and the Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA, USA</affiliation><description>Address reprint requests to Donald Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Sentinel lymphadenectomy (SLND) is fast becoming the procedure of choice for staging primary breast carcinoma and melanoma. This simpler and less morbid alternative to standard lymph node dissection can increase the rate of detecting nodal disease. Because the tumor status of the regional lymph nodes remains a significant prognostic tool in both diseases, clinicians may use SLND to facilitate selection of patients for adjuvant chemotherapy. Although SLND has been validated by institutions worldwide, it continues to evolve. The following review will examine current data and controversies surrounding this emerging technology.</abstract><note>Supported by Grant No. CA29605 from the National Cancer Institute and by funding from the Wrather Family Foundation (Los Angeles), the Ben B. and Joyce E. Eisenberg Foundation (Los Angeles), the Associates for Breast Cancer Research, and the Fashion Footwear Association of New York.</note><relatedItem type="host"><titleInfo><title>Seminars in Oncology</title></titleInfo><titleInfo type="abbreviated"><title>YSONC</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">200102</dateIssued></originInfo><identifier type="ISSN">0093-7754</identifier><identifier type="PII">S0093-7754(00)X0063-2</identifier><part><date>200102</date><detail type="issue"><title>Adjuvant Therapy</title></detail><detail type="volume"><number>28</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>138</end></extent><extent unit="pages"><start>41</start><end>52</end></extent></part></relatedItem><identifier type="istex">7A7AE56241211D63D73EFA367CB8AD1BF783D287</identifier><identifier type="DOI">10.1016/S0093-7754(01)90044-2</identifier><identifier type="PII">S0093-7754(01)90044-2</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003942 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003942 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7A7AE56241211D63D73EFA367CB8AD1BF783D287
|texte= The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer
}}
| This area was generated with Dilib version V0.6.31. |  |